Develco Pharma Schweiz AG

Quick facts

Phase 3 pipeline

• Naloxone HCl PR tablets · Addiction Medicine / Emergency Medicine
  Naloxone HCl is a competitive opioid receptor antagonist that blocks the effects of opioids by binding to opioid receptors without activating them.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Develco Pharma Schweiz AG portfolio CI brief
• Develco Pharma Schweiz AG pipeline updates RSS